As India and the European Union meet today for a Summit in New Delhi to iron out the differences over a Free Trade Agreement, nearly two thousand people living with HIV and the international medical humanitarian organisation Medecins Sans Frontieres (MSF) protested in the streets of the Indian capital to warn that remaining harmful provisions in the agreement could have a severely negative impact on access to affordable medicine for people in developing countries.
“We have watched too many people die in places where we work because the medicines they need are too expensive,” said Unni Karunakara, international president of MSF, adding: “We cannot allow this trade deal to shut down the pharmacy of the developing world.”
The FTA has implications way beyond the medicines sector – where intellectual property rights are a main focus, aiming essentially to tackle high Indian tariffs in several retail sectors. The EU particularly insists on the reduction of tariffs on wines and spirits, dairy products and cars. The proposed FTA would cut import duties on over 90% of all tradable goods during the next 10-year period and scale up bilateral trade in goods and services to $200 billion by 2013.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze